9-ING-41

• CAT Number: I017651
• CAS Number: 1034895-42-5
• Molecular Formula: C₂₂H₁₃FN₂O₅
• Molecular Weight: 404.35
• Purity: ≥95%
• Storage: Store at -20°C
• IUPAC Name: 3-(5-fluoro-1-benzofuran-3-yl)-4-(5-methyl-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
• InChI: InChI=1S/C22H13FN2O5/c1-25-7-13(11-5-17-18(6-15(11)25)30-9-29-17)19-20(22(27)24-21(19)26)14-8-28-16-3-2-10(23)4-12(14)16/h2-8H,9H2,1H3,(H,24,26,27)
• InChIKey: FARXPFGGGGLENU-UHFFFAOYSA-N
• SMILES: CN1C=C(C2=CC3=C(C=C21)OCO3)C4=C(C(=O)NC4=O)C5=COC6=C5C=C(C=C6)F

9-ING-41（Cat No.:I017651） is a highly potent inhibitor of glycogen synthase kinase 3 (GSK-3) that exhibits significant antitumor activity. By targeting centrosomes and microtubule-bound GSK3β, 9-ING-41 induces proapoptosis (programmed cell death) and cell cycle arrest in cancer cells. It effectively disrupts the function of GSK-3, a key regulator of multiple signaling pathways involved in cell proliferation and survival. Through its mechanism of action, 9-ING-41 shows promise as a therapeutic agent for the treatment of various cancers.

Reference

[1]. Irina N Gaisina, et al. From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells. J Med Chem. 2009 Apr 9;52(7):1853-63.[2]. Wu X, et al. Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma. Blood. 2019 Jul 25;134(4):363-373.[3]. Hiroo Kuroki, et al. 9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer. Sci Rep. 2019 Dec 27;9(1):19977.[4]. Ugolkov AV, et al. 9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma. Anticancer Drugs. 2018 Sep;29(8):717-724.